Your session is about to expire
← Back to Search
Nonsteroidal Anti-inflammatory Drug
162mg daily aspirin dose for Prophylaxis of Preeclampsia
Phase 4
Waitlist Available
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
BMI at enrollment >/= 30
plan for ASA for preeclampsia prevention
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average for 10 months
Awards & highlights
Study Summary
This study is evaluating whether a higher dose of aspirin may help prevent preeclampsia in high risk women.
Eligible Conditions
- Prophylaxis of Preeclampsia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average for 10 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average for 10 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of Diagnosis of preeclampsia
Secondary outcome measures
Incidence of aspirin resistance based on incomplete inhibition of TBx2
Trial Design
2Treatment groups
Active Control
Group I: 81 mg daily aspirin doseActive Control1 Intervention
obese women >30 BMI at risk for preeclampsia will receive recommended 81mg ASA
Group II: 162mg daily aspirin doseActive Control1 Intervention
obese women >30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
Find a Location
Who is running the clinical trial?
Ohio State UniversityLead Sponsor
821 Previous Clinical Trials
500,935 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger